Your browser doesn't support javascript.
loading
Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
Cristiano, Edgardo; Alonso, Ricardo; Alvez Pinheiro, Amelia; Bacile, Elizabeth A; Balbuena, María Eugenia; Ballario, Carlos; Barboza, Andrés G; Bestoso, Santiago; Burgos, Marcos; Cáceres, Fernando; Carnero Contentti, Edgar; Carrá, Adriana; Crespo, Ernesto; Curbelo, María Celeste; Deri, Normah; Fernandez, Jorge; Fernández Liguori, Nora; Fiol, Marcela; Gaitán, María Ines; Garcea, Orlando; Giunta, Diego; Halfon, Mario J; Hryb, Javier P; Jacobo, Miguel; Kohler, Eduardo; Linares, Ramiro; Luetic, Geraldine G; Martínez, Alejandra D; Míguez, Jimena; Nofal, Pedro G; Patrucco, Liliana; Piedrabuena, Raúl; Rojas, Juan Ignacio; Rotta Escalante, Roberto; Saladino, María Laura; Silva, Berenice A; Sinay, Vladimiro; Steinberg, Judith D; Tarulla, Adriana; Vétere, Santiago A; Villa, Andrés; Vrech, Cárlos; Ysrraelit, María Célica; Correale, Jorge.
Afiliação
  • Cristiano E; Centro de esclerosis múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Argentina. Electronic address: edgardo.cristiano@hospitalitaliano.org.ar.
  • Alonso R; Clínica de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina; Sanatorio Guemes, Buenos Aires, Argentina.
  • Alvez Pinheiro A; Hospital San Martín, Paraná, Entre Ríos, Argentina.
  • Bacile EA; Instituto Neurociencias Cordoba, Argentina.
  • Balbuena ME; Seccion de Neuroinmunologia y Enfermedades Desmielinizantes, Servicio de Neurologia, Hospital de clinicas Jose de San Martin, Argentina.
  • Ballario C; NeuroRosario, Rosario, Argentina.
  • Barboza AG; Hospital Central de Mendoza, Argentina.
  • Bestoso S; Servicio Neurología, Hospital Escuela Corrientes, Argentina.
  • Burgos M; Hospital San Bernardo, Salta, Argentina.
  • Cáceres F; INEBA, Institute of Neuoscience Buenos Aires, Argentina.
  • Carnero Contentti E; Department of Neuroscience - Neuroimmunology Unit, Hospital Alemán, Buenos Aires, Argentina.
  • Carrá A; MS Section Hospital Britanico Buenos Aires, Argentina; Fundación Favaloro/INECO, Buenos Aires, Argentina.
  • Crespo E; Universisad Nacional del sur, Bahia Blanca, Buenos Aires, Argentina.
  • Curbelo MC; MS Section Hospital Britanico Buenos Aires, Argentina; Policlinico Municipal Sofía T. de Santamarina, Buenos Aires, Argentina.
  • Deri N; Centro de Investigaciones Diabaid, Argentina; Hospital Fernández de Buenos Aires, Argentina.
  • Fernandez J; Práctica Privada, Argentina.
  • Fernández Liguori N; Hospital Enrique Tornu, Buenos Aires, Argentina; Sanatorio Guemes, Buenos Aires, Argentina.
  • Fiol M; Department of Neurology, Institute for Neurological Research Dr Raul Carrea, FLENI, Argentina.
  • Gaitán MI; Department of Neurology, Institute for Neurological Research Dr Raul Carrea, FLENI, Argentina.
  • Garcea O; Clínica de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina.
  • Giunta D; Clinical Research Section, Hospital Italiano de Buenos Aires, Argentina.
  • Halfon MJ; Hospital Británico de Buenos Aires, Argentina; Hospital Municipal de Vicente López Prof. Dr. Bernardo Houssay, Argentina.
  • Hryb JP; Servicio de Neurología, Hospital Cárlos G. Durand, CABA, Buenos Aires, Argentina.
  • Jacobo M; RIAPEM (Red Integral Asistencial al Paciente con EM), Santiago del Estero, Argentina.
  • Kohler E; Fundación Sinapsis Santa Rosa La Pampa, Argentina.
  • Linares R; Axis Neurociencias Bahia Blanca, Argentina.
  • Luetic GG; Instituto de Neurociencias de Rosario, Argentina.
  • Martínez AD; MS Section Hospital Britanico Buenos Aires, Argentina.
  • Míguez J; Centro de esclerosis múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Argentina.
  • Nofal PG; Hospital de Clínicas Ntra Sra del Carmen, San Miguel de Tucumán, Argentina.
  • Patrucco L; Centro de esclerosis múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Argentina.
  • Piedrabuena R; Instituto Lennox/Clinica Reina Fabiola, Córdoba, Argentina.
  • Rojas JI; Centro de esclerosis múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Argentina.
  • Rotta Escalante R; Fundación FACENE, Buenos Aires, Argentina.
  • Saladino ML; INEBA, Institute of Neuoscience Buenos Aires, Argentina.
  • Silva BA; Clínica de Esclerosis Múltiple, Hospital Ramos Mejía, Buenos Aires, Argentina.
  • Sinay V; Fundación Favaloro/INECO, Buenos Aires, Argentina.
  • Steinberg JD; MS Section Hospital Britanico Buenos Aires, Argentina.
  • Tarulla A; Hospital de Agudos Parmenio Piñero, Municipalidad de Ciudad de Buenos Aires, MCBA, Argentina.
  • Vétere SA; Sección de Enfermedades Desmielinizantes HIGA "Gral. San Martín" de la ciudad de La Plata, Argentina.
  • Villa A; Sección Neuroinmunología, Hospital Ramos Mejia, Buenos Aires, Argentina.
  • Vrech C; Departamento de Enfermedades desmielinizantes, Sanatorio Allende Cordoba, Argentina.
  • Ysrraelit MC; Department of Neurology, Institute for Neurological Research Dr Raul Carrea, FLENI, Argentina.
  • Correale J; Department of Neurology, Institute for Neurological Research Dr Raul Carrea, FLENI, Argentina.
J Neurol Sci ; 385: 217-224, 2018 02 15.
Article em En | MEDLINE | ID: mdl-29406907
ABSTRACT
One of the biggest challenges in multiple sclerosis (MS) is the definition of treatment response/failure in order to optimize treatment decisions in affected patients. The objective of this consensus was to review how disease activity should be assessed and to propose recommendations on the identification of treatment failure in RRMS patients in Argentina.

METHODS:

A panel of experts in neurology from Argentina, dedicated to the diagnosis and care of MS patients, gathered both virtually and in person during 2016 and 2017 to carry out a consensus recommendation on the identification of treatment failure in RRMS patients. To achieve consensus, the methodology of "formal consensus-RAND/UCLA method" was used.

RESULTS:

Recommendations were established based on published evidence and the expert opinion. Recommendations focused on disease management, disease activity markers and treatment failure identification were determined. Main consensus were ≥2 relapses during the first year of treatment and/or ≥3 new or enlarged T2 or T1 GAD+ lesions and/or sustained increase of ≥2 points in EDSS or ≥100% in T25FW defines treatment failure in RRMS patients.

CONCLUSIONS:

The recommendations of this consensus guidelines attempts to optimize the health care and management of patients with MS in Argentina.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Falha de Tratamento / Esclerose Múltipla Recidivante-Remitente / Consenso Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Argentina Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Falha de Tratamento / Esclerose Múltipla Recidivante-Remitente / Consenso Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans País/Região como assunto: America do sul / Argentina Idioma: En Ano de publicação: 2018 Tipo de documento: Article